BILLERICA, Mass.--(BUSINESS WIRE)--Aug. 28, 2018--
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless
insulin pump technology with its Omnipod® Insulin
Management System, today announced that management will present at two
upcoming investor conferences in New York City, New York:
The Baird 2018 Global Healthcare Conference on Wednesday, September 5,
2018, at 10:15 a.m. (Eastern Time).
The 16th Annual Morgan Stanley Global Healthcare Conference onThursday, September 13, 2018, at 11:45 a.m. (Eastern Time).
To listen to live audio webcasts of the presentations, please visit http://investors.insulet.com.
Replays of the webcasts will also be available following the events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod, by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, more than
140,000 users across the globe rely on Insulet’s Omnipod Insulin
Management System to bring simplicity and freedom to their lives.
On July 1, Insulet assumed direct operations of its Omnipod Insulin
Management System product line in Europe, including sales, marketing,
training and customer support activities. This allows Insulet to be
closer to the diabetes community and identify opportunities to support
European customer needs over the long-term, as Insulet does in the
United States and Canada.
For more information, please visit: www.insulet.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180828005123/en/
Source: Insulet Corporation
Investor Relations and Media Contact:
Deborah R. Gordon, 978-600-7717
Investor Relations and Corporate Communications